Arrow Financial Corp Trims Position in Eli Lilly And Co (LLY)

Share on StockTwits

Arrow Financial Corp decreased its holdings in Eli Lilly And Co (NYSE:LLY) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,457 shares of the company’s stock after selling 128 shares during the quarter. Arrow Financial Corp’s holdings in Eli Lilly And Co were worth $632,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Ironwood Financial llc purchased a new position in Eli Lilly And Co during the 4th quarter worth $30,000. Csenge Advisory Group purchased a new position in Eli Lilly And Co during the 3rd quarter worth $58,000. Atwood & Palmer Inc. raised its position in Eli Lilly And Co by 267.0% during the 4th quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock worth $85,000 after buying an additional 534 shares during the last quarter. Cornerstone Advisors Inc. raised its position in Eli Lilly And Co by 21.3% during the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after buying an additional 136 shares during the last quarter. Finally, First Command Bank raised its position in Eli Lilly And Co by 31.3% during the 4th quarter. First Command Bank now owns 834 shares of the company’s stock worth $96,000 after buying an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 80.84% of the company’s stock.

A number of equities analysts have commented on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Citigroup downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price objective for the company. in a research report on Sunday, December 2nd. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 4th. UBS Group cut their price objective on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Finally, Barclays restated a “buy” rating and set a $130.00 price objective on shares of Eli Lilly And Co in a research report on Sunday, January 20th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $111.41.

In related news, SVP Alfonso G. Zulueta sold 4,000 shares of the stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $113.74, for a total transaction of $22,748,000.00. Following the completion of the sale, the insider now directly owns 118,600,804 shares in the company, valued at $13,489,655,446.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 817,843 shares of company stock worth $94,595,335. Corporate insiders own 0.11% of the company’s stock.

NYSE:LLY opened at $119.65 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.53 and a current ratio of 1.91. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $121.84. The firm has a market cap of $125.67 billion, a PE ratio of 21.56, a P/E/G ratio of 1.91 and a beta of 0.37.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same period last year, the company earned $1.14 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly And Co will post 5.6 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be paid a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.16%. Eli Lilly And Co’s dividend payout ratio is 40.54%.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://macondaily.com/2019/02/14/arrow-financial-corp-trims-position-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: What is the Coverage Ratio?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply